Advertisement

Extended-Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized Controlled Trial

      Background

      Cocaine dependence is a substantial public health problem, yet there are no clearly effective medication treatments. Amphetamine and topiramate have both shown promise for the treatment of cocaine dependence in preclinical and early-stage clinical studies.

      Methods

      Eighty-one cocaine-dependent adults were randomized to receive a combination of extended-release mixed amphetamine salts (MAS-ER) and topiramate or placebo for 12 weeks under double-blind conditions. MAS-ER doses were titrated over 2 weeks to a maximum dose of 60 mg daily, and topiramate doses were titrated over 6 weeks to a maximum dose of 150 mg twice daily. All participants received a supportive behavioral intervention. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence as measured by urine toxicology confirmed self-report.

      Results

      The overall proportion of participants who achieved 3 consecutive weeks of abstinence was larger in the extended-release mixed amphetamine salts and topiramate group (33.3%) than in placebo group (16.7%). There was a significant moderating effect of baseline total number of cocaine use days (Wald χ2 = 3.75, df = 1, p = .05) on outcome, suggesting that the combination treatment was most effective for participants with a high baseline frequency of cocaine use.

      Conclusions

      The results of this study supported our hypothesis that the combination of MAS-ER and topiramate would be superior to placebo in achieving 3 weeks of consecutive abstinence. These findings provide evidence that the combination of MAS-ER and topiramate is efficacious in promoting abstinence in cocaine-dependent individuals.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration
        Results from the 2010 National Survey on Drug Use and Health: Summary of national findings.
        Office of Applied Studies, Rockville, MD2011
        • Compton W.M.
        • Thomas Y.F.
        • Stinson F.S.
        • Grant B.F.
        Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions.
        Arch Gen Psychiatry. 2007; 64: 566-576
        • Dutra L.
        • Stathopoulou G.
        • Basden S.L.
        • Leyro T.M.
        • Powers M.B.
        • Otto M.W.
        A meta-analytic review of psychosocial interventions for substance use disorders.
        Am J Psychiatry. 2008; 165: 179-187
        • de Lima M.S.
        • de Oliveira Soares B.G.
        • Reisser A.A.
        • Farrell M.
        Pharmacological treatment of cocaine dependence: A systematic review.
        Addiction. 2002; 97: 931-949
        • Leiderman D.B.
        • Shoptaw S.
        • Montgomery A.
        • Bloch D.A.
        • Elkashef A.
        • LoCastro J.
        • et al.
        Cocaine Rapid Efficacy Screening Trial (CREST): A paradigm for the controlled evaluation of candidate medications for cocaine dependence.
        Addiction. 2005; 100: 1-11
        • Karila L.
        • Gorelick D.
        • Weinstein A.
        • Noble F.
        • Benyamina A.
        • Coscas S.
        • et al.
        New treatments for cocaine dependence: A focused review.
        Int J Neuropsychopharmacol. 2008; 11: 425-438
        • White F.J.
        • Kalivas P.W.
        Neuroadaptations involved in amphetamine and cocaine addiction.
        Drug Alcohol Depend. 1998; 51: 141-153
        • Amato L.
        • Davoli M.
        • Perucci C.A.
        • Ferri M.
        • Faggiano F.
        • Mattick R.P.
        An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research.
        J Subst Abuse Treat. 2005; 28: 321-329
        • Berrettini W.H.
        • Lerman C.E.
        Pharmacotherapy and pharmacogenetics of nicotine dependence.
        Am J Psychiatry. 2005; 162: 1441-1451
        • Martinez D.
        • Carpenter K.M.
        • Liu F.
        • Slifstein M.
        • Broft A.
        • Friedman A.C.
        • et al.
        Imaging dopamine transmission in cocaine dependence: Link between neurochemistry and response to treatment.
        Am J Psychiatry. 2011; 168: 634-641
        • Schubiner H.
        • Saules K.K.
        • Arfken C.L.
        • Johanson C.E.
        • Schuster C.R.
        • Lockhart N.
        • et al.
        Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence.
        Exp Clin Psychopharmacol. 2002; 10: 286-294
        • Levin F.R.
        • Evans S.M.
        • Brooks D.J.
        • Garawi F.
        Treatment of cocaine dependent treatment seekers with adult ADHD: Double-blind comparison of methylphenidate and placebo.
        Drug Alcohol Depend. 2006; 87: 20-29
        • Grabowski J.
        • Roache J.D.
        • Schmitz J.M.
        • Rhoades H.
        • Creson D.
        • Korszun A.
        Replacement medication for cocaine dependence: Methylphenidate.
        J Clin Psychopharmacol. 1997; 17: 485-488
        • Grabowski J.
        • Rhoades H.
        • Schmitz J.
        • Stotts A.
        • Daruzska L.A.
        • Creson D.
        • et al.
        Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial.
        J Clin Psychopharmacol. 2001; 21: 522-526
        • Shearer J.
        • Wodak A.
        • van Beek I.
        • Mattick R.P.
        • Lewis J.
        Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.
        Addiction. 2003; 98: 1137-1141
        • Dackis C.A.
        • Kampman K.M.
        • Lynch K.G.
        • Pettinati H.M.
        • O'Brien C.P.
        A double-blind, placebo-controlled trial of modafinil for cocaine dependence.
        Neuropsychopharmacology. 2005; 30: 205-211
        • Poling J.
        • Oliveto A.
        • Petry N.
        • Sofuoglu M.
        • Gonsai K.
        • Gonzalez G.
        • et al.
        Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
        Arch Gen Psychiatry. 2006; 63: 219-228
        • Anderson A.L.
        • Reid M.S.
        • Li S.H.
        • Holmes T.
        • Shemanski L.
        • Slee A.
        • et al.
        Modafinil for the treatment of cocaine dependence.
        Drug Alcohol Depend. 2009; 104: 133-139
        • Mooney M.E.
        • Herin D.V.
        • Schmitz J.M.
        • Moukaddam N.
        • Green C.E.
        • Grabowski J.
        Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.
        Drug Alcohol Depend. 2009; 101: 34-41
        • Castells X.
        • Casas M.
        • Perez-Mana C.
        • Roncero C.
        • Vidal X.
        • Capella D.
        Efficacy of psychostimulant drugs for cocaine dependence.
        Cochrane Database Syst Rev. 2010; 2010 (CD007380)
        • Sofuoglu M.
        • Dudish-Poulsen S.
        • Poling J.
        • Mooney M.
        • Hatsukami D.K.
        The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users.
        Addict Behav. 2005; 30: 1125-1134
        • Alvarez Y.
        • Farre M.
        • Fonseca F.
        • Torrens M.
        Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis.
        J Subst Abuse Treat. 2010; 38: 66-73
        • Kampman K.M.
        • Pettinati H.
        • Lynch K.G.
        • Dackis C.
        • Sparkman T.
        • Weigley C.
        • et al.
        A pilot trial of topiramate for the treatment of cocaine dependence.
        Drug Alcohol Depend. 2004; 75: 233-240
        • Brodie J.D.
        • Case B.G.
        • Figueroa D.
        • Dewey S.L.
        • Robinson J.A.
        • Wanderling J.A.
        • et al.
        Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.
        Am J Psychiatry. 2009; 166: 1269-1277
        • White H.S.
        • Brown S.D.
        • Woodhead J.H.
        • Skeen G.A.
        • Wolf H.H.
        Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism.
        Epilepsia. 2000; 41: S17-S20
        • Skradski S.
        • White H.S.
        Topiramate blocks kainate-evoked cobalt influx into cultured neurons.
        Epilepsia. 2000; 41: S45-S47
        • Johnson B.A.
        • Ait-Daoud N.
        • Bowden C.L.
        • DiClemente C.C.
        • Roache J.D.
        • Lawson K.
        • et al.
        Oral topiramate for treatment of alcohol dependence: A randomised controlled trial.
        Lancet. 2003; 361: 1677-1685
        • Johnson B.A.
        • Rosenthal N.
        • Capece J.A.
        • Wiegand F.
        • Mao L.
        • Beyers K.
        • et al.
        Topiramate for treating alcohol dependence: A randomized controlled trial.
        JAMA. 2007; 298: 1641-1651
        • Johnson B.A.
        • Ait-Daoud N.
        • Akhtar F.Z.
        • Javors M.A.
        Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial.
        Arch Intern Med. 2005; 165: 1600-1605
        • Johnson B.A.
        • Swift R.M.
        • Addolorato G.
        • Ciraulo D.A.
        • Myrick H.
        Safety and efficacy of GABAergic medications for treating alcoholism.
        Alcohol Clin Exp Res. 2005; 29: 248-254
        • Johnson B.A.
        • Swift R.M.
        • Ait-Daoud N.
        • DiClemente C.C.
        • Javors M.A.
        • Malcolm Jr, R.J.
        Development of novel pharmacotherapies for the treatment of alcohol dependence: Focus on antiepileptics.
        Alcohol Clin Exp Res. 2004; 28: 295-301
        • Schiffer W.K.
        • Gerasimov M.R.
        • Marsteller D.A.
        • Geiger J.
        • Barnett C.
        • Alexoff D.L.
        • et al.
        Topiramate selectively attenuates nicotine-induced increases in monoamine release.
        Synapse. 2001; 42: 196-198
        • Nies A.S.
        Principles of Therapeutics.
        in: 10th ed. Goodman and Gilman's the pharmacological basis of therapeutics. 54. McGraw-Hill, New York2001
        • Carroll K.M.
        • Rounsaville B.J.
        • Nich C.
        • Gordon L.T.
        • Wirtz P.W.
        • Gawin F.
        One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence.
        Arch Gen Psychiatry. 1994; 51: 989-997
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders.
        4th ed., text revision. American Psychiatric Association, Washington, DC2000
        • Carroll K.M.
        • Om S.
        • Nuro K.
        Compliance Enhancement: A Manual for the Psychopharmacology of Drug Abuse and Dependence (Yale University Psychotherapy Development Center Training Series No. 4).
        Yale University Psychotherapy Development Center, West Haven, CT1999
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV Axis I DisordersPatient Edition (SCID-I/P, Version 2.0).
        Biometrics Research Department, New York State Psychiatric Institute, New York1995
        • Litten R.
        • Allen J.
        Measuring Alcohol Consumption: Psychosocial and Biochemical Methods.
        in: The Humana Press, Totowa, NJ1992: 41-72
        • Winhusen T.
        • Somoza E.
        • Ciraulo D.A.
        • Harrer J.M.
        • Goldsmith R.J.
        • Grabowski J.
        • et al.
        A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence.
        Drug Alcohol Depend. 2007; 91: 141-148
        • SAS Institute
        SAS version 9.2..
        Cary, NC, SAS Institute2009
        • Fournier J.C.
        • DeRubeis R.J.
        • Hollon S.D.
        • Dimidjian S.
        • Amsterdam J.D.
        • Shelton R.C.
        • et al.
        Antidepressant drug effects and depression severity: A patient-level meta-analysis.
        JAMA. 2010; 303: 47-53
        • Bisaga A.
        • Aharonovich E.
        • Garawi F.
        • Levin F.R.
        • Rubin E.
        • Raby W.N.
        • et al.
        Utility of lead-in period in cocaine dependence pharmacotherapy trials.
        Drug Alcohol Depend. 2005; 77: 7-11
        • Kampman K.M.
        • Volpicelli J.R.
        • Mulvaney F.
        • Rukstalis M.
        • Alterman A.I.
        • Pettinati H.
        • et al.
        Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence.
        Addict Behav. 2002; 27: 251-260
        • Johnson B.A.
        • Roache J.D.
        • Ait-Daoud N.
        • Wells L.T.
        • Wallace C.L.
        • Dawes M.A.
        • et al.
        Effects of acute topiramate dosing on methamphetamine-induced subjective mood.
        Int J Neuropsychopharmacol. 2007; 10: 85-98
        • Anton R.F.
        • O'Malley S.S.
        • Ciraulo D.A.
        • Cisler R.A.
        • Couper D.
        • Donovan D.M.
        • et al.
        Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial.
        JAMA. 2006; 295: 2003-2017